Haemophilia

Papers
(The H4-Index of Haemophilia is 24. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Eptacog beta for the management of patients with haemophilia A and B with inhibitors: A European perspective842611252
WFH Guidelines for the Management of Hemophilia, 3rd edition880
Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A61
Real‐world use of emicizumab in patients with haemophilia A: Bleeding outcomes and surgical procedures58
The European Association for Haemophilia and Allied Disorders (EAHAD) Coagulation Factor Variant Databases: Important resources for haemostasis clinicians and researchers54
The role of telemedicine in the delivery of health care in the COVID‐19 pandemic50
The World Federation of Hemophilia Annual Global Survey 1999‐201845
Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study40
Occurrence rates of haemophilia among males in the United States based on surveillance conducted in specialized haemophilia treatment centres40
Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real‐world experience from a large comprehensive treatment centre in the US37
Effects of emicizumab on APTT, one‐stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors34
Emicizumab prophylaxis: Prospective longitudinal real‐world follow‐up and monitoring33
Synovitis and synovectomy in haemophilia30
Telehealth for delivery of haemophilia comprehensive care during the COVID‐19 pandemic29
Biological mechanisms underlying inter‐individual variation in factor VIII clearance in haemophilia28
Genetic causes of haemophilia in women and girls28
World Federation of Hemophilia Gene Therapy Registry28
Delivery of AAV‐based gene therapy through haemophilia centres—A need for re‐evaluation of infrastructure and comprehensive care: A Joint publication of EAHAD and EHC27
Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‐YOND extension study27
Development and evaluation of the population pharmacokinetic models for FVIII and FIX concentrates of the WAPPS‐Hemo project26
Uncertainty in an era of transformative therapy for haemophilia: Addressing the unknowns26
Bleeding of unknown cause and unclassified bleeding disorders; diagnosis, pathophysiology and management25
Low immunogenicity of emicizumab in persons with haemophilia A25
Physiotherapy interventions for pain management in haemophilia: A systematic review24
Patient perspectives regarding gene therapy in haemophilia: Interviews from the PAVING study24
Long‐term safety and efficacy of emicizumab for up to 5.8 years and patients’ perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A24
0.029072999954224